Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ

Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ

Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly characterized. Thus, there is an unmet clinical need fo...

Full description

Bibliographic Details
Main Authors: Kirsty E. Waddington, Artemis Papadaki, Leda Coelewij, Marsilio Adriani, Petra Nytrova, Eva Kubala Havrdova, Anna Fogdell-Hahn, Rachel Farrell, Pierre Dönnes, Inés Pineda-Torra, Elizabeth C. Jury
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Immunology
Subjects:
immunogenicity
anti-drug antibodies
multiple sclerosis
metabolomics
cholesterol
machine learning
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01527/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01527/full

Similar Items